Sunday, December 4

Spanish coronavirus vaccine | Brussels signs a joint purchase contract with Hipra for 250 million of its vaccine against Covid-19


  • A total of 14 member states have already joined the joint purchase agreement for the first Spanish vaccine against covid-19

  • The formula, which is being reviewed by the European Medicines Agency, could be approved this fall

The European Comission reported on Tuesday the signing of a joint purchase agreement with the pharmaceutical company Hipra to ensure the supply 250 million doses of the first Spanish vaccine against the coronavirus responsible for covid-19. According to the European authorities, for the time being there are at least 14 member states that they will participate in this first purchase and that in the coming months they will receive vials of the immunization designed, tested and manufactured in Spain.

The purchase agreement with Brussels is the first that has transcended in relation to the Hipra vaccine but it may not be the last. As explained just a few days ago by the pharmaceutical company’s director of R&D and records, Elia Torroella, in an interview with EL PERIÓDICO, the company is also holding talks with countries in Latin America, Southeast Asia and the Middle East medium to export its vaccine against covid-19.

The Hipra vaccine, which has already been successfully tested on thousands of volunteerswill be supplied as booster dose in people over 16 years old already vaccinated against covid-19. At the moment, the formula is in the last phase of review by the European Medicines Agency (EMA), who will finally decide on its final approval. According to the pharmaceutical company, the definitive approval could arrive just in time for the start of the vaccination campaign this fall.

Also Read  Digital transformation will drive investment in technology mergers and acquisitions

European vaccine portfolio

Related news

The Commissioner for Health of the European Commission, Stella Kyriakideshas stated that doses of Hipra “add one more option to the extensive portfolio of European vaccines”. The joint purchase agreement of vaccines with Hipra, in fact, complements the contracts previously signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica, BioNtech-Pfizer, Moderna, Novavax and Valnevawhich ensures some 4,200 million doses for the community market within the framework of the vaccination strategy against covid-19.

The Commissioner for Health of the European Commission, Stella Kyriakideshas stated that doses of Hipra “add one more option to the extensive portfolio of European vaccines”. “With covid-19 infections on the rise in Europe, we must guarantee the maximum preparation as we approach the fall and winter months,” Kyriakides argued in a statement issued on Tuesday. Right now, with 81.4% of the European population vaccinated with a complete guideline, the objective of Brussels is to expand the vaccination coverage with booster dose.


www.elperiodico.com

Leave a Reply

Your email address will not be published. Required fields are marked *